Key Highlights

  • Definium Therapeutics (NASDAQ: DFTX) reported a second positive Phase 3 GAD study for DT120 ODT.
  • Armata Pharmaceuticals (NYSE American: ARMP) received FDA Breakthrough Therapy Designation for AP-SA02.
  • Corbus Pharmaceuticals (NASDAQ: CRBP) reported favorable Phase 1b obesity data for CRB-913.
  • Capricor Therapeutics (NASDAQ: CAPR) was upgraded by B. Riley to Buy, with the price target raised to $21 from $5.

Several biotech names posted positive clinical or regulatory developments in the same news cycle, spanning anxiety disorder, infectious disease, obesity, cardiomyopathy, neuro-oncology imaging, and Manufacturing operations.

Definium Therapeutics (NASDAQ: DFTX): Second Positive Phase 3 GAD Study

Definium Therapeutics reported its second positive Phase 3 GAD study for DT120 ODT, with the Panorama trial meeting the Week 12 HAM-A primary endpoint at the 100 microgram dose, showing a 5.1-point placebo-adjusted improvement and rapid onset by Day 2. Safety remained generally well tolerated, with no drug-related serious adverse events, supporting a broader anxiety and depression regulatory package following prior positive Voyage and Emerge readouts.

Armata Pharmaceuticals (NYSE American: ARMP): Breakthrough Therapy Designation

Armata Pharmaceuticals announced the FDA granted Breakthrough Therapy designation to intravenous AP-SA02 as an adjunctive therapy for complicated Staphylococcus aureus bacteremia, covering both MSSA and MRSA. The designation builds on existing QIDP and Fast Track status following positive Phase 1b/2a diSArm study results that demonstrated favorable safety, accelerated clinical cure, zero relapses through Day 28, and encouraging biomarker signals.

Corbus Pharmaceuticals (NASDAQ: CRBP): Positive Phase 1b Obesity Data

Corbus Pharmaceuticals announced favorable Phase 1b CANYON-1 trial results evaluating once-daily oral CRB-913 for obesity, demonstrating statistically significant weight reduction across all cohort dosages, highlighted by a 5.0% average decrease in the 60 mg arm at 12 weeks with no observed plateau. The safety profile was tolerable, with no suicidal Ideation signals observed, paving the way for regulatory interactions and a planned Phase 2 monotherapy trial targeted for the first half of 2027.

Capricor Therapeutics (NASDAQ: CAPR): B. Riley Upgrade to Buy

Capricor Therapeutics was upgraded by B. Riley to Buy from Neutral, with the firm raising its price target to $21 from $5. The upgrade points to a positive setup ahead of the November 22 FDA target date for deramiocel in Duchenne muscular dystrophy, alongside potential open-label extension readouts at the World Muscle Society that may spark a pre-PDUFA stock re-rating.

Telix Pharmaceuticals (NASDAQ: TLX): Pixclara FDA Approval

Telix Pharmaceuticals announced FDA approval of Pixclara (TLX101-CDx), marking the first targeted FET-PET agent cleared in the U.S. for glioma characterization across adult and pediatric populations. The approval provides clinicians a tool to differentiate tumor recurrence from treatment-induced effects, broadening the company's neuro-oncology diagnostic pipeline.

Scinai Immunotherapeutics (NASDAQ: SCNI): Shares Surge 47% on Strategic Refocus

Scinai Immunotherapeutics shares closed up 47% at $2.44 after the company terminated its PC111 option and license agreement with PinCell following an ungranted extension request. Scinai is redirecting R&D efforts toward its NanoAb pipeline and IL-17 candidates to conserve Capital for its expanding CDMO operations, which held roughly $3.1 million in contracted customer orders as of August 16 while projecting around $5 million in 2026 CDMO sales.